Fennec Pharmaceuticals Inc. (TSE:FRX - Get Free Report) Senior Officer Adrian J. Haigh sold 22,223 shares of the stock in a transaction dated Tuesday, April 23rd. The stock was sold at an average price of C$9.32, for a total transaction of C$207,029.47.
Adrian J. Haigh also recently made the following trade(s):
- On Monday, April 15th, Adrian J. Haigh bought 22,222 shares of Fennec Pharmaceuticals stock. The shares were acquired at an average price of C$2.31 per share, with a total value of C$51,332.82.
Fennec Pharmaceuticals Stock Performance
TSE:FRX traded down C$0.02 on Tuesday, reaching C$12.80. 800 shares of the company's stock were exchanged, compared to its average volume of 726. The company has a debt-to-equity ratio of 881.09, a current ratio of 3.29 and a quick ratio of 10.17. The firm has a market cap of C$346.11 million, a price-to-earnings ratio of -12.55 and a beta of 0.35. Fennec Pharmaceuticals Inc. has a 52 week low of C$9.27 and a 52 week high of C$15.43. The stock has a fifty day simple moving average of C$13.51 and a 200-day simple moving average of C$12.72.
Fennec Pharmaceuticals (TSE:FRX - Get Free Report) last released its quarterly earnings data on Thursday, March 21st. The biopharmaceutical company reported C($0.14) EPS for the quarter, missing analysts' consensus estimates of C$0.02 by C($0.16). Fennec Pharmaceuticals had a negative net margin of 75.50% and a negative return on equity of 1,005.59%. The firm had revenue of C$13.25 million during the quarter, compared to the consensus estimate of C$12.88 million. As a group, sell-side analysts predict that Fennec Pharmaceuticals Inc. will post 0.4202312 earnings per share for the current year.
Fennec Pharmaceuticals Company Profile
(
Get Free Report)
Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Fennec Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fennec Pharmaceuticals wasn't on the list.
While Fennec Pharmaceuticals currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
